06996 德琪醫藥－Ｂ
按盘价 
0.720 -0.020 (-2.703%) 盈利能力分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 资产回报率 (%) | -30.908% | -25.596% | -22.793% | -148.143% | -77.074% |
| 股东资金回报率 (%) | -40.632% | -29.286% | -24.135% | -236.185% | N/A |
| 资本运用回报率 (%) | -40.708% | -34.168% | -27.334% | -96.226% | -45.295% |
边际利润分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 毛利率 (%) | 81.735% | 82.433% | 84.080% | N/A | N/A |
| 未计利息、税项、折旧及摊销前利润率 (%) | -875.260% | -375.632% | -2298.189% | N/A | N/A |
| 税前边际利润率 (%) | -863.506% | -375.613% | -2278.595% | N/A | N/A |
| 纯利率 (%) | -863.506% | -375.613% | -2278.595% | N/A | N/A |
变现能力分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 流动比率 (X) | 6.506 X | 4.966 X | 15.139 X | 20.770 X | 16.813 X |
| 速动比率 (X) | 6.426 X | 4.940 X | 15.123 X | 20.770 X | 16.813 X |
财务杠杆分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 总负债 / 总资产比率 (%) | 29.112% | 20.019% | 6.385% | 4.902% | 173.391% |
| 总债项 / 总资产比率 (%) | 12.419% | 2.705% | 0.579% | 0.342% | 0.548% |
| 净债项 / 总资产比率 (%) | -60.960% | -80.838% | -88.361% | -97.011% | -97.743% |
| 总债项 / 股东资金比率 (%) | 17.520% | 3.383% | 0.619% | 0.360% | N/A |
| 长期债项 / 股东资金比率 (%) | 16.887% | 2.746% | 0.164% | 0.197% | N/A |
| 净债项 / 股东资金比率 (%) | -85.994% | -101.071% | -94.388% | -102.011% | N/A |
| 净现金 / (债项) ($) | 9.87亿 | 17.32亿 | 22.60亿 | 30.99亿 | 7.43亿 |
| 每股净现金 / (债项) ($) | 1.462 | 2.566 | 3.384 | 4.617 | -- |
| 总债项 / 资本运用比率 (%) | 14.080% | 3.292% | 0.618% | 0.359% | 0.583% |
| 利息盈利率 (X) | N/A | N/A | N/A | N/A | N/A |
营运效率分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 存货周转率日数 (日) | 373.492日 | 80.899日 | 205.452日 | N/A | -- |
| 应收贸易帐周转率日数 (日) | 106.973日 | 41.909日 | 88.887日 | N/A | N/A |
| 应付贸易帐周转率日数 (日) | 31.668日 | 10.595日 | 18.714日 | N/A | N/A |
| 备注： | 实时报价更新时间为19/11/2024 13:30 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) () | RMB -167,033,000 |
| 增长率 | -23.623% |
| 每股盈利/(亏损) | RMB -0.270 |
| 每股账面资产净值 (¥) | RMB 1.472 |